Table 2 Patients who experienced disease progression or initiation of therapy.
No | Sex | Age at FL diagnosis | Involved GI tract | Stage | Events | Time to events (years) | Outcome | Follow-up period (years) |
|---|---|---|---|---|---|---|---|---|
1 | M | 62 | Duodenum, jejunum, rectum | I | Perigastric LN swelling | 0.9 | Alive with lymphoma after treatment | 10.2 |
Initiation of rituximab monotherapy | 1.1 | |||||||
2 | M | 70 | Duodenum | I | Mesenteric LN swelling | 1.2 | Alive with lymphoma | 9.5 |
3 | M | 64 | Duodenum | I | Initiation of rituximab and bendamustine therapy | 2.0 | Alive, NED with treatment | 5.8 |
4 | F | 41 | Duodenum, stomach, rectum | I | Inguinal LN swelling | 2.0 | Alive, NED with treatment | 22.8 |
Initiation of rituximab monotherapy | 3.5 | |||||||
5 | F | 40 | Duodenum | I | Initiation of rituximab monotherapy | 2.7 | Alive, NED with treatment | 12.5 |
6 | M | 57 | Jejunum | I | Multiple intraabdominal LN swelling | 3.1 | Alive with lymphoma | 10.6 |
7 | F | 60 | Duodenum | I | Mesenteric LN swelling | 5.4 | Alive, NED with treatment | 8.7 |
Initiation of radiotherapy | 5.8 | |||||||
8 | F | 75 | Duodenum | I | Cervical and mesenteric LN swelling | 7.1 | Alive, NED with treatment | 8.9 |
Initiation of obinutuzumab and bendamustine therapy | 7.5 |
